Core Viewpoint - The company forecasts a significant increase in adjusted net profit for 2025, driven by a dual strategy of organic growth and external acquisitions, leading to improved profitability and operational efficiency [1][2]. Group 1: Financial Performance Forecast - The company expects 2025 revenue to be no less than 3 billion yuan, representing a year-on-year growth of at least 16% [1]. - Adjusted net profit is projected to be no less than 380 million yuan, with a year-on-year increase of at least 40%, while net profit is expected to be no less than 340 million yuan, reflecting a growth of at least 34% [1]. - The performance forecast aligns with expectations due to the company's effective dual strategy and operational improvements [1]. Group 2: Growth Drivers - The company anticipates robust organic growth and contributions from acquisitions, with revenue growth expected to be driven by double-digit growth in beauty and health services, and high growth in sub-health medical services [1][2]. - The integration of the acquired company, Nai Rui Er, is expected to enhance operational efficiency and contribute to revenue growth in 2025 [1][2]. - The company reported strong performance during the year-end "Double Festival" period, with revenue from its main business segments showing positive year-on-year growth [1]. Group 3: Profitability Enhancement - The company forecasts an adjusted net profit margin of 12.7% for 2025, an increase of 2 percentage points year-on-year, driven by a higher proportion of high-margin medical services and operational efficiency improvements [2]. - The integration of Nai Rui Er is expected to further enhance profitability through effective resource integration and operational empowerment [2]. Group 4: Strategic Outlook - The company completed the acquisition of Si Yan Li on January 7, 2026, which will contribute to revenue growth and operational efficiency, leveraging the integration experience from Nai Rui Er [2]. - The company is optimistic about its growth potential under the "super brand, super chain, super digitalization" strategy, which is expected to enhance market bargaining power [2]. Group 5: Earnings Forecast and Valuation - The company maintains its profit forecast for 2025 and has increased the 2026 net profit estimate by 20% to 430 million yuan, with projections for 2027 at 540 million yuan [2]. - The current stock price corresponds to a price-to-earnings ratio of 13x for 2026 and 10x for 2027, with a target price of 42 HKD, indicating a potential upside of 57% [2].

Group 1 - The company announced the acquisition of 100% equity in Siyuanli for 1.25 billion RMB (approximately 1.369 billion HKD), aiming to further industry consolidation [1] - Siyuanli, established in 1996, is the third-largest beauty service brand in China, with 182 stores as of June 2024, including 163 beauty stores and 19 medical beauty stores across 48 cities [1] - Post-acquisition, the company's total store count will exceed 700, enhancing market share and accelerating the "Double Beauty + Double Healthcare" strategic layout [1] Group 2 - The company increased its stake in Nairui to 90% after acquiring 70% equity for a total consideration of 350 million RMB, with Nairui being the second-largest traditional beauty service brand in China [2] - In July 2024, the company announced the inclusion of 75 remaining Nairui stores through franchising, adding a total of 150 new stores to its network [2] - Nairui's revenue reached 277 million RMB in the first half of 2025, with adjusted net profit margin improving from 6.5% before acquisition to 10.4% post-acquisition [2] Group 3 - The company held a strategic upgrade conference on November 19, announcing three major strategies: Super Brand, Super Chain, and Super Digitalization [3] - The Super Brand strategy focuses on integrating the top three brands in the industry, including Meili Tianyuan, Nairui, and Siyuanli, to strengthen brand advantages [3] - The company has invested over 200 million RMB in digitalization, achieving double-digit growth in new member acquisition and maintaining a member retention rate of 80% in the following year [3] Group 4 - The company maintains a buy rating, adjusting the 2025 adjusted earnings per share forecast from 1.34 RMB to 1.59 RMB, with new forecasts for 2026 and 2027 set at 2.05 RMB and 2.29 RMB, respectively [3] - The target price has been raised from 19.84 HKD to 37.13 HKD, indicating a potential upside of 41% [3]